おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Neuros Medical
company
About
Neuros Medical develops neurostimulation therapies for patients suffering with unmet medical needs.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $20M
- Industries
- Health Care,Life Science,Medical,Medical Device,Therapeutics
- Founded date
- Jan 1, 2008
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$23.87M
Neuros Medical has raised a total of
$23.87M
in funding over 2 rounds. Their latest funding was raised on
Aug 7, 2017 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 7, 2017 | Series A | $20M | 1 | — | — | Detail |
| Jul 18, 2012 | Series Unknown | $3.50M | 1 |
Boston Scientific
|
— | Detail |
| Mar 1, 2009 | Series Unknown | $375K | 1 |
Jumpstart-up
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
Neuros Medical is funded by 2 investors.
Jumpstart-up
and Boston Scientific
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Jumpstart-up
|
Yes | Series Unknown |
|
Boston Scientific
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
